US cost effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

Study evaluated the cost effectiveness of polatuzumab vedotin combined with bendamustine and rituximab for treatment of relapsed DLBCL.